Pazopanib

Catalog No.S3012 Synonyms: GW786034

Pazopanib Chemical Structure

Molecular Weight(MW): 437.52

Pazopanib is a novel multi-target inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFR, FGFR, c-Kit and c-Fms with IC50 of 10 nM, 30 nM, 47 nM, 84 nM, 74 nM, 140 nM and 146 nM in cell-free assays, respectively.

Size Price Stock Quantity  
USD 70 In stock
USD 210 In stock

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

2 Customer Reviews

  • J Virol 2011 85(5), 2296-303. Pazopanib purchased from Selleck.

    Three RCC cell lines treated with different concentrations of TKI and HDIL-2 and incubated for 48 h. Microscopic images show apoptotic materials 48 h following treatment (arrows show the apoptotic materials in the pazopanib-treated cells).

    Expert Opin Pharmacother 2014 15(11), 1489-99. Pazopanib purchased from Selleck.

Purity & Quality Control

Choose Selective VEGFR Inhibitors

Biological Activity

Description Pazopanib is a novel multi-target inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFR, FGFR, c-Kit and c-Fms with IC50 of 10 nM, 30 nM, 47 nM, 84 nM, 74 nM, 140 nM and 146 nM in cell-free assays, respectively.
Targets
VEGFR1 [1]
(Cell-free assay)
VEGFR2 [1]
(Cell-free assay)
VEGFR3 [1]
(Cell-free assay)
c-Kit [1]
(Cell-free assay)
PDGFR [1]
(Cell-free assay)
10 nM 30 nM 47 nM 74 nM 84 nM
In vitro

Pazopanib potently inhibits VEGF-induced phosphorylation of VEGFR2 in HUVEC cells with IC50 of 8 nM. [1] PPazopanib shows dose-dependent growth inhibition in all synovial sarcoma cell lines including SYO-1 and HS-SY-II cells. Proliferation of SYO-1 and HS-SY-II cells is inhibited even at 1 µg/mL of Pazopanib and is completely abolished at 5 µg/mL. Pazopanib induces G1 arrest, and thereby suppresses the growth of synovial sarcoma cells. Phosphorylation of Akts, GSK-3β, JNKs, p70 S6 Kinase, and mTOR is suppressed in Pazopanib-treated SYO-1 cells compared with that in the vehicle-treated cells. [2] Pazopanib between 20 m g/mL and 22.5 m g/mL shows an increasing reduction of RPE cell viability. [3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
human EoL-1-cell cell MVnHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NVr0UFh5UW6qaXLpeIlwdiCxZjDoeY1idiCHb1ytNU1k\WyuIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJIlkPTB;Mj64PYUuODVizszN NWDBSFJ5W0GQR1XS
human AN3-CA cell MW\Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MYDJcohq[mm2aX;uJI9nKGi3bXHuJGFPOy2FQTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUGwMlA2KG6P NHPtWIhUSU6JRWK=
human CGTH-W-1 cell MXXHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MYrJcohq[mm2aX;uJI9nKGi3bXHuJGNIXEhvVz2xJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9OFAvODFibl2= MlPtV2FPT0WU
human GDM-1 cell M3fxfWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M3PYcGlvcGmkaYTpc44hd2ZiaIXtZY4hT0SPLUGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xNFMvQTlibl2= NYjYcnBGW0GQR1XS
human A204 cell M3Tvemdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NI\hWYVKdmirYnn0bY9vKG:oIHj1cYFvKEF{MESgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xNFkvODZibl2= M3;venNCVkeHUh?=
human G-402 cell M2\KN2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NGPrNXpKdmirYnn0bY9vKG:oIHj1cYFvKEdvNECyJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9OVMyNjh2IH7N MWXTRW5ITVJ?
human MFE-296 cell M4XRSWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M37aWmlvcGmkaYTpc44hd2ZiaIXtZY4hVU[HLUK5OkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvPTlyMkKg{txO M4XmTHNCVkeHUh?=
human NOS-1 cell M4PZXWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NFz0UlJKdmirYnn0bY9vKG:oIHj1cYFvKE6RUz2xJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKGmlNUC9NE43PTl6NzFOwG0> NUnBclVSW0GQR1XS
human KG-1 cell MV7Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? Ml3zTY5pcWKrdHnvckBw\iCqdX3hckBMTy1zIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MD63NVc2PSEQvF2= M3OwOnNCVkeHUh?=
human HT55 cell Mn;SS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MVHJcohq[mm2aX;uJI9nKGi3bXHuJGhVPTViY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1yLkm4O|gyKM7:TR?= NWPuNWNHW0GQR1XS
human MG-63 cell NWXlZ2czT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NWO0SWhCUW6qaXLpeIlwdiCxZjDoeY1idiCPRz22N{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVEvODBzNE[g{txO MmjvV2FPT0WU
human CCF-STTG1 cell NVHCcJpnT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NVe0RVZGUW6qaXLpeIlwdiCxZjDoeY1idiCFQ1[tV3RVTzFiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3Ojef-8kEBKSzVyPUGuNFQ6QDFizszN MXXTRW5ITVJ?
human RT-112 cell NE\QR3ZIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NYLjPWFuUW6qaXLpeIlwdiCxZjDoeY1idiCUVD2xNVIh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0yNjFyM{e2JO69VQ>? NYL1[odZW0GQR1XS
human MC-IXC cell NX\zVVBsT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MVTJcohq[mm2aX;uJI9nKGi3bXHuJG1ENUm[QzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUGuNVE2OTJizszN NFPFfYdUSU6JRWK=
human HUTU-80 cell MVzHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NXTiTJhxUW6qaXLpeIlwdiCxZjDoeY1idiCKVWTVMVgxKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OS5{OEGwN{DPxE1? NFvzcJBUSU6JRWK=
human MV-4-11 cell NX7oNVd6T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NGfm[2xKdmirYnn0bY9vKG:oIHj1cYFvKE2YLUStNVEh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0yNjN2NUCxJO69VQ>? M1PXPHNCVkeHUh?=
human LCLC-103H cell NGq3fm9Iem:5dHigbY5pcWKrdHnvckBie3OjeR?= NX\zR5F2UW6qaXLpeIlwdiCxZjDoeY1idiCOQ1zDMVExO0hiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeR?= NUixflQ5W0GQR1XS
human G-401 cell MmnsS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NGDkWXhKdmirYnn0bY9vKG:oIHj1cYFvKEdvNECxJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NU41PjR{MTFOwG0> NUjhWIdPW0GQR1XS
human A704 cell MXzHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NV:1UYs4UW6qaXLpeIlwdiCxZjDoeY1idiCDN{C0JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NU43ODN{MzFOwG0> Mo\jV2FPT0WU
human ESS-1 cell MWrHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NX[zeHJWUW6qaXLpeIlwdiCxZjDoeY1idiCHU2OtNUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVEvPjB|OU[g{txO NH7COItUSU6JRWK=
human HLE cell NEHnbIhIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MVHJcohq[mm2aX;uJI9nKGi3bXHuJGhNTSClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTFwNkO4NFQh|ryP MVfTRW5ITVJ?
human NY cell NUnk[WV[T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MYDJcohq[mm2aX;uJI9nKGi3bXHuJG5[KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OS56NEiyNUDPxE1? M4DSSXNCVkeHUh?=
human A427 cell NUPlWYlWT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NEPnN2xKdmirYnn0bY9vKG:oIHj1cYFvKEF2MkegZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xMlk5ODd3IN88US=> M1\0XHNCVkeHUh?=
human SK-N-DZ cell NHW2SWdIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MkixTY5pcWKrdHnvckBw\iCqdX3hckBUUy2QLVTaJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9Nk4xOjN6MTFOwG0> NVLNPHRTW0GQR1XS
human J82 cell MlSyS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M3PKemlvcGmkaYTpc44hd2ZiaIXtZY4hUjh{IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;Mj6wOlA5QCEQvF2= NXjG[GhVW0GQR1XS
human GI-1 cell MnqzS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M{fDdmlvcGmkaYTpc44hd2ZiaIXtZY4hT0lvMTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUKuNlI6PTFizszN NUHBW3YyW0GQR1XS
human NCI-H716 cell NF2xRY9Iem:5dHigbY5pcWKrdHnvckBie3OjeR?= M4nMU2lvcGmkaYTpc44hd2ZiaIXtZY4hVkOLLVi3NVYh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0zNjNzNkOzJO69VQ>? NUH0TVNTW0GQR1XS
human SF126 cell M2HafGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NHj5U25KdmirYnn0bY9vKG:oIHj1cYFvKFOIMUK2JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9Nk41PzR3OTFOwG0> MlziV2FPT0WU
human H4 cell M2\NWWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NEjqSYJKdmirYnn0bY9vKG:oIHj1cYFvKEh2IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;Mj61NVI3OiEQvF2= M2e3UHNCVkeHUh?=
human LB831-BLC cell MXjHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NHLweFdKdmirYnn0bY9vKG:oIHj1cYFvKEyEOEOxMWJNSyClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTJwNUS1OlYh|ryP MnvYV2FPT0WU
human HCC1395 cell MYrHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M{LkV2lvcGmkaYTpc44hd2ZiaIXtZY4hUEOFMUO5OUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVIvPThzNU[g{txO NU\NVGlFW0GQR1XS
human LK-2 cell MnLsS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MYrJcohq[mm2aX;uJI9nKGi3bXHuJGxMNTJiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1{Lk[0OVY6KM7:TR?= MkLTV2FPT0WU
human G-361 cell Mof2S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? Mn2wTY5pcWKrdHnvckBw\iCqdX3hckBINTN4MTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUOuNFQxQDJizszN MUTTRW5ITVJ?
human NCI-H2342 cell NV\GO2I2T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NX\uWpJEUW6qaXLpeIlwdiCxZjDoeY1idiCQQ1mtTFI{PDJiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeT6gTWM2OD1|LkGzN|E3KM7:TR?= MorDV2FPT0WU
human SK-LU-1 cell  M1[3Nmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NXjnUWROUW6qaXLpeIlwdiCxZjDoeY1idiCVSz3MWU0yKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:Oy5zOEe2O{DPxE1? NUD0eI45W0GQR1XS
human IGROV-1 cell  NHf3d|hIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NILEVZRKdmirYnn0bY9vKG:oIHj1cYFvKEmJUl;WMVEh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0{NjJ2N{GzJO69VQ>? MY\TRW5ITVJ?
human EB2 cell MVjHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MVzJcohq[mm2aX;uJI9nKGi3bXHuJGVDOiClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTNwMkixOlgh|ryP NWnWVFZMW0GQR1XS
human CAL-54 cell MmfmS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MmrMTY5pcWKrdHnvckBw\iCqdX3hckBESUxvNUSgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2zMlI5OzZ5IN88US=> MX;TRW5ITVJ?
human LB1047-RCC cell MnzRS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MXjJcohq[mm2aX;uJI9nKGi3bXHuJG9EXUJvTTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUOuN|MyOzZ6IN88US=> MljwV2FPT0WU
Daudi cell MXfHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NGD1TGdKdmirYnn0bY9vKG:oIHj1cYFvKEyEMUC0O{1TS0NiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1|LkWzNVY1KM7:TR?= M4HzdnNCVkeHUh?=
human Daudi cell MVLHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MkX5TY5pcWKrdHnvckBw\iCqdX3hckBF[XWmaTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUOuOlYzOTlizszN MV3TRW5ITVJ?
human A172 cell Ml7XS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NGLOV3BKdmirYnn0bY9vKG:oIHj1cYFvKEFzN{KgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2zMlc{PzlizszN MWHTRW5ITVJ?
human KGN cell MVjHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M{jLdWlvcGmkaYTpc44hd2ZiaIXtZY4hU0eQIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;ND6wOlcxQSEQvF2= NX\GUXM3W0GQR1XS
human SNG-M cell MmL6S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? Mn:0TY5pcWKrdHnvckBw\iCqdX3hckBUVkdvTTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUSuNFg3PjlizszN Mo\xV2FPT0WU
human SW1710 cell NVnOVWNvT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M2rqOWlvcGmkaYTpc44hd2ZiaIXtZY4hW1dzN{GwJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9OE41PzNzODFOwG0> MlXXV2FPT0WU
human HT29 cells MX7Qdo9tcW[ncnH0bY9vKGG|c3H5 NVrIXlJ1SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDIWFI6KGOnbHzzJIlvKHOncoXtJINwdnSjaX7pcochdWWmaYXt NFLPcoMyQDZ{MEO4Ni=>
human A375P cells MlriVJJwdGmoZYLheIlwdiCjc4PhfS=> MY\BcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEF|N{XQJINmdGy|IHnuJJNmenWvIHPvcpRicW6rbnegcYVlcXWv MV:xPFYzODN6Mh?=
human HN5 cells Mm\PVJJwdGmoZYLheIlwdiCjc4PhfS=> MkLJRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCKTkWgZ4VtdHNiaX6gd4VzfW1iY3;ueIFqdmmwZzDt[YRqfW1? MlTtNVg3OjB|OEK=
HUVEC MWHGeY5kfGmxbjDhd5NigQ>? MWexJO69VQ>? Mmq4OkBp MmPuRY51cWGwZ3nv[4VvcWNiYXP0bZZqfHliaX6gTHVXTUNiYYPz[ZN{\WRiYYOgbY5pcWKrdHnvckBw\iC2dXLlJIZwem2jdHnvckBifCByLkGgeW0h[W[2ZYKgOkBpenNiYomgUYF1emmpZXygZZN{[Xl? NE\pfZkzPDB|NkC0Ni=>
human Daoy cell MnLCS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NVztWmlvUW6qaXLpeIlwdiCxZjDoeY1idiCGYX;5JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9OE44Pzl2OTFOwG0> MXzTRW5ITVJ?
human DMS-273 cell M2jEfGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MmLKTY5pcWKrdHnvckBw\iCqdX3hckBFVVNvMkezJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9OE46PjJyMjFOwG0> Mmq1V2FPT0WU
human KU812 cell M1P4R2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NYXCcWJmUW6qaXLpeIlwdiCxZjDoeY1idiCNVUixNkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVUvOzd6MUKg{txO NWr0flRjW0GQR1XS
human NCI-H727 cell M1HKcWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MlnQTY5pcWKrdHnvckBw\iCqdX3hckBPS0lvSEeyO{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVUvPDB7MEGg{txO NGLKWHBUSU6JRWK=
human P30-OHK cell MnTzS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MWXJcohq[mm2aX;uJI9nKGi3bXHuJHA{OC2RSFugZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME21MlQ3QTRizszN MoLWV2FPT0WU
human MIA-PaCa-2 cell NXnwZ|NsT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MXTJcohq[mm2aX;uJI9nKGi3bXHuJG1KSS2SYVPhMVIh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF02NjZyNE[2JO69VQ>? NYrPS5BRW0GQR1XS
human TT cell M4nPPWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M2X4eGlvcGmkaYTpc44hd2ZiaIXtZY4hXFRiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD13Lk[2NlQh|ryP MlHxV2FPT0WU
human DK-MG cell NFvKcotIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NX:0V41XUW6qaXLpeIlwdiCxZjDoeY1idiCGSz3NS{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVUvPzJyMkig{rxu NH7OXYFUSU6JRWK=

... Click to View More Cell Line Experimental Data

In vivo The mice treated with 30 mg/kg or 100 mg/kg Pazopanib reveals a significant decrease in tumor burden compared with the mice treated with vehicle or 10 mg/kg Pazopanib. Treatment with Pazopanib is well-tolerated and there is no significant difference in the body weight among the mice in each group. [2]

Protocol

Solubility (25°C)

In vitro DMSO 87 mg/mL warmed (198.84 mM)
Water <1 mg/mL
Ethanol <1 mg/mL
In vivo

* 1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 437.52
Formula

C21H23N7O2S

CAS No. 444731-52-6
Storage powder
in solvent
Synonyms GW786034

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT02300545 Recruiting Sarcoma, Soft Tissue|Soft Tissue Sarcoma Washington University School of Medicine April 8, 2015 Phase 2
NCT00674024 Completed Neoplasms|Lymphoma National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) October 7, 2008 Phase 1
NCT01716416 Recruiting Squamous Cell Carcinoma of the Head and Neck Washington University School of Medicine May 31, 2013 Phase 1
NCT01462630 Recruiting Adult Angiosarcoma|Recurrent Adult Soft Tissue Sarcoma|Stage III Adult Soft Tissue Sarcoma|Stage IV Adult Soft Tissue Sarcoma Fox Chase Cancer Center|National Cancer Institute (NCI) November 3, 2011 Phase 2
NCT01468922 Completed Sarcoma|Stomach Neoplasms|Neoplasms National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) October 24, 2011 Phase 1
NCT02342600 Not yet recruiting Gastrointestinal Stromal Tumors Sarcoma Alliance for Research through Collaboration|Novartis January 2017 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

VEGFR Signaling Pathway Map

Related VEGFR Products

Tags: buy Pazopanib | Pazopanib supplier | purchase Pazopanib | Pazopanib cost | Pazopanib manufacturer | order Pazopanib | Pazopanib distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID